-
Some issues are a result of still being paper driven as timely reports and real time information are not available, but they are not the only government agency in this scenario, only one of the most critical though. Also, some members of Congress don’t use computers either and felt uncomfortable...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Medical Records, Pharma, FDA, Congress, integration, CMS, Leavitt
-
Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-25-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
-
The post is a summary of how things look today and under related reading I have included some past posts that may offer a few more details on how the shift it taking place today. Things are also happening and humming as well in China and you can search and find some recent relative posts here as...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-20-2008
Filed under:
Filed under: Pharma/FDA News, My Commentaries, healthcare, Pharma, clinical trials, R and D, India, Economics, Mayo Clinic, Outsourcing, Employment, China pharma
-
At first you may say this is old stuff, but the new version does much more than just take pictures on it’s way through your system, this one disperses medication, and that’s the whole idea is to have a pill put the medicine on target, where it needs to be with digestive problems such as treating Crohn...
-
Will there be more Crestor for all? I am guessing the side effects of rising blood sugar levels still may need to be addressed, even with the report to determine which issue is more profound. With the cost of the product versus the generic version, this might also add some impact as to availability...
-
The general public as a whole are lost when it comes to the complete understanding of how a clinical trial can benefit their potential treatment plans. There is enough information on the web by all means, but how do you get the information to an individual and explain both the potential benefits...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-07-2008
Filed under:
Filed under: Medically Related, Technology, drugs, healthcare, EHR, Pharma, PHR, clinical trials, Software integration, Point of Care, Personalized Clinical Trials
-
New abbreviation here to become acquainted with (PGx) which is pharmacogenics, and one more move in the direction of personalized medicine by big Pharma as the marketing of blockbuster drugs slowly evolves to a new business model with genomic data input becoming a part of the process to bring new drugs...
-
This particular statement really bothers me, is CMS now going to take on the role of “doctor here? “ The Bush administration argued that Medicare officials had the right to decide whether the expense incurred for a given item, not just the item itself, was “reasonable and necessary.” How...
-
I will once more mention a potential change of paradigms here with educating the public. Each patient who took the drug is unique. Do we have any information on other drugs they were taking at the same time? Groups will continue to advise against the use until the full facts are known...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-31-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, PHR, FDA, Marketing, paradigms, personal heatlh records
-
This actually a pretty good start and I have had my own campaign of sorts going on with getting the FDA up to speed, and they are definitely having to play catch up, as are some other government agencies. In prior posts I had written that some clinical studies were still being written in long hand...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-31-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, healthcare, Education, Pharma, FDA, Personal Health Records, GSK, Consumer Healthcare, Drug Interactions
-
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
-
As this begins the week of the “Never-Never” rules with Medicare and with Sepsis being included on the hospital acquired listings, the group is calling for standards to prevent, which includes the use of minocycline and rifampin impregnated catheters. Severe sepsis is common, with over 750...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-03-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, healthcare, microsoft, Medical Records, Silverlight, Pharma, Cook Medical, CMS, Heatlhcare, Catheters, hospital acquired infections, Server 2008, Never-Never, Sepsis, Thomas Jefferson University, Line Sepsis, Vanderbilt University
-
Genomics is back on the list for Congress, with creating an additional new agency and a focus on collecting the necessary information to allow research and development. Also included would be guidelines and rules related to genetic and pharmacogenomic tests to bring both Pharma and medical...
-
Interesting article with some good background information about drugs that are close to or are related to the "street drugs" as we know them. There are definitely a number of researchers who want to delve into this further, but with bad raps and being illegal in their "street drug"...
-
I am guessing this stands to be topic for all in the Pharma business to keep an eye on. There are those in the Indian government too with reservations. The whole idea here is to save money over what the same might cost in the US, as reported earlier, 1/5 is the cost for R and D, thus this...